1,5-Anhydro-l-rhamnitol

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 氧烷类
• 英文名称: 1,5-Anhydro-l-rhamnitol
• 英文别名: 2-methyloxane-3,4,5-triol
• 化学式: C₆H₁₂O₄
• 分子量: 148.16
• InChiKey: KBVSUNBCTPQWJL-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -1.6
• 重原子数：
  10
• 可旋转键数：
  0
• 环数：
  1.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  69.9
• 氢给体数：
  3
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  1,5-Anhydro-l-rhamnitol 、 三氟乙酸酐 、 二氯甲烷 生成 [6-methyl-4,5-bis[(2,2,2-trifluoroacetyl)oxy]oxan-3-yl] 2,2,2-trifluoroacetate
  参考文献：
  名称：

  KONIG, WILFRIED A.;MISCHNICK-LUBBECKE, PETRA;BRASSAT, BARBEL;LUTZ, SABINE+, CARBOHYDR. RES., 183,(1988) N 1, C. 11-17

  摘要：

  DOI：

文献信息

• [EN] MANNOSE DERIVATIVES FOR TREATING BACTERIAL INFECTIONS<br/>[FR] DÉRIVÉS DE MANNOSE POUR LE TRAITEMENT D'INFECTIONS BACTÉRIENNES
  申请人：VERTEX PHARMA

  公开号：WO2013134415A1

  公开（公告）日：2013-09-12

  The present invention relates to compounds useful for the treatment or prevention of bacteria infections. These compounds have formula I: The invention also provides pharmaceutically acceptable compositions containing the compounds and methods of using the compositions in the treatment of bacteria infections. Finally, the invention provides processes for making compounds of the invention.

  本发明涉及用于治疗或预防细菌感染的化合物。这些化合物的公式为I：。发明还提供了包含这些化合物的药用可接受组合物，以及使用组合物治疗细菌感染的方法。最后，发明提供了制造本发明化合物的方法。
• [EN] GLYCOSIDE COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS THEREOF<br/>[FR] COMPOSÉS DE GLYCOSIDE ET COMPOSITIONS PHARMACEUTIQUES DE CEUX-CI
  申请人：CT SE LLC

  公开号：WO2010017480A1

  公开（公告）日：2010-02-11

  The present invention provides glycoside compounds, methods of preparing such compounds, pharmaceutical compositions comprising such compounds, and a method for the treatment of hyperproliferative diseases using the same.

  本发明提供了糖苷化合物、制备这种化合物的方法、包含这种化合物的药物组合物，以及使用这种化合物治疗过度增殖性疾病的方法。
• [EN] SMALL MOLECULE BASED ANTIBODY-RECRUITING COMPOUNDS FOR CANCER TREATMENT<br/>[FR] COMPOSÉS DE RECRUTEMENT D'ANTICORPS À BASE DE PETITES MOLÉCULES POUR LE TRAITEMENT DU CANCER
  申请人：UNIV YALE

  公开号：WO2017023994A1

  公开（公告）日：2017-02-09

  The present invention relates to chimeric (including bifunctional) compounds, compositions comprising those compounds and methods of treating cancer in a patient or subject, especially including metastatic cancer where cancer cells exhibit overexpression (heightened expression) of cell surface urokinase-type plasminogen activator receptor (urokinase receptor) compared to normal (non-cancerous) cells. The compounds bind to the urokinase-type plasminogen activator receptor (uPAR) on the surface of a cancer cell, including a metastatic cancer cell, and consequently recruit native antibodies of the patient or subject where the antibodies can selectively degrade and/or deactivate targeted cancer cells through antibody-dependent cellular phagocytosis and antibody-dependent cellular cytotoxicity (ADCC) and/or complement dependent cytotoxicity (CDC) against a large number and variety of cancers, thus providing cancer cell death and an inhibition of growth, elaboration and/or metastasis of the cancer, including remission and cure of the patient's cancer.

  本发明涉及嵌合（包括双功能）化合物，包含这些化合物的组合物以及治疗患者或受试者癌症的方法，特别是包括转移性癌症，其中癌细胞相对于正常（非癌细胞）细胞表现出细胞表面尿激酶型纤溶酶原激活剂受体（尿激酶受体）的过表达（增强表达）。这些化合物与癌细胞表面的尿激酶型纤溶酶原激活剂受体（uPAR）结合，包括转移性癌细胞，从而招募患者或受试者的天然抗体，这些抗体可以通过抗体依赖性细胞吞噬和抗体依赖性细胞毒性（ADCC）和/或补体依赖性细胞毒性（CDC）选择性地降解和/或使靶向的癌细胞失活，针对大量和各种癌症，从而提供癌细胞死亡并抑制癌症的生长、扩散和/或转移，包括患者癌症的缓解和治愈。
• EXTRACELLULAR TARGETED DRUG CONJUGATES
  申请人：Hutchinson Charles R.

  公开号：US20110064752A1

  公开（公告）日：2011-03-17

  The present invention relates to, inter alia, extracellular drug conjugates (EDC) in which an antibody or other targeting agent (e.g. a targeting moiety) is linked to a drug through a linker (e.g. a non-cleavable linker). These conjugates are useful in the treatment of disease and/or as a tool in the evaluation of biological systems.

  本发明涉及细胞外药物结合物（EDC），其中抗体或其他靶向剂（例如靶向基团）通过连接剂（例如不可切割的连接剂）与药物连接。这些结合物在治疗疾病和/或作为评估生物系统的工具中很有用。
• PROCESS FOR PREPARING A PENTOPYRANOSYL NUCLEIC ACID CONJUGATE
  申请人：Miculka Christian

  公开号：US20090221793A1

  公开（公告）日：2009-09-03

  The invention relates to a process for preparing a conjugate that includes a pentopyranosyl nucleic acid and a biomolecule. The process includes the steps of providing a pentopyranosyl nucleic acid having at least two pentopyranosyl nucleotide subunits that are covalently linked between carbon 4 and carbon 2 of their respective pentopyranosyl rings. The pentopyranosyl nucleic acid also has an electrophilic reactive group. A biomolecule having a nucleophilic reactive group is also provided. The electrophilic reactive group of the pentopyranosyl nucleic acid and the nucleophilic reactive group of the biomolecule are reacted to form a covalent bond.

  本发明涉及一种制备包括五碳糖核酸和生物分子的共轭物的方法。该方法包括以下步骤：提供一种具有至少两个五碳糖核苷酸亚基的五碳糖核酸，这些亚基在它们各自的五碳糖环的碳4和碳2之间共价键结合。五碳糖核酸还具有一个亲电反应基团。同时提供一种具有亲核反应基团的生物分子。将五碳糖核酸的亲电反应基团和生物分子的亲核反应基团反应以形成共价键。